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Current strategies for osteochondral regeneration:
from stem cells to pre-clinical approaches
Ma´rcia T Rodrigues1,2, Manuela E Gomes1,2 and Rui L Reis1,2Damaged cartilage tissue has no functional replacement
alternatives and current therapies for bone injury treatment are
far from being the ideal solutions emphasizing an urgent need
for alternative therapeutic approaches for osteochondral (OC)
regeneration.The tissue engineering field provides new
possibilities for therapeutics and regeneration in
rheumatology and orthopaedics, holding the potential for
improving the quality of life of millions of patients by exploring
new strategies towards the development of biological
substitutes to maintain, repair and improve OC tissue
function. Numerous studies have focused on the
development of distinct tissue engineering strategies that
could result in promising solutions for this delicate interface.
In order to outperform currently used methods, novel tissue
engineering approaches propose, for example, the design of
multi-layered scaffolds, the use of stem cells, bioreactors or
the combination of clinical techniques.
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Introduction
Osteochondral (OC) interfaces are part of the joint, being
a specialized and integrated structure consisting of
multiple connective tissue elements, including muscles,
tendons, ligaments, synovium, cartilage, and bone, orga-
nized to permit stability and movement of the human
skeleton.
OC injuries can lead to joint malfunction and ultimately
to the development of degenerative diseases such as
osteoarthritis. With an increasing aging population, OA
represents a significant socio-economical burden world-Please cite this article in press as: Rodrigues MT, et al. Current strategies for osteochondral regen
j.copbio.2011.04.006
www.sciencedirect.comwide. Although several procedures are available on the
clinical market, an ideal solution has yet to be found in
order to fulfil all necessary requirements for a long-term
successful regenerative approach.
This paper is aimed at reviewing distinct strategies aim-
ing at a successful OC regeneration, involving cells,
scaffolds, bioreactors or a combination of these elements.
The rationale for currently used techniques as well as
some promising studies in animal models will also be
discussed in this review in order to highlight the state-of-
the-art in OC over the past few years (Figure 1).
One of the most challenging goals in bone and cartilage
tissue engineering (TE) is the creation of an engineered
OC interface to repair damaged areas. Similarly to the
natural milieu, an engineered interface should distri-
bute everyday mechanical stresses with low-friction
load bearing, while interacting with different structural
and biological needs in a stable environment. This is
particularly more demanding and unique if one con-
siders the distinctive requirements of bone and cartilage
tissues as well as the several OC systems found in the
human body, dependent on their location and function-
ality.
Several materials, shapes, stiffness and chemical compo-
sitions were described for bone [1–8] and cartilage scaf-
folds [8–11,12,13–20,21], considering the relevance of
scaffold architecture to sustain the mechanical stresses of
the joint as well as to guide the cells into the desired
phenotype, and promoting a complete integration of the
OC system in order to restore tissue functionality.
The selection of cells also plays an important element in
this delicate interface headed for engineered grafts. Sev-
eral potential cell sources were successfully described for
bone [22–26], and cartilage [17,22–27], which are likely to
be useful for OC strategies [8].
The subsequent step towards the clinical application is
the up-scale and custom made production of the OC
implants to fit perfectly to the injured area and to provide
the biological and structural needs required to restore
tissue function. In order to automate andmake the system
cost-effective, several bioreactor models [28,29] were
designed and have been showing promising results.
Osteochondral defects (OCD)
Most OC lesions or defects (OCD) and OC injury-
associated diseases lead to loss of integrity or stabilityeration: from stem cells to pre-clinical approaches, Curr Opin Biotechnol (2011), doi:10.1016/
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Clinical and tissue engineering strategies to promote the regeneration of osteochondral defects.at the articular surface with resultant decrease range of
motion of the involved joint, and, ultimately, premature
osteoarthritis (OA) [30]. Although OCDs occur as a
result of repetitive trauma within the joint, several
factors, such as ischemia, genetics, abnormal vascula-
ture, and metabolic disorders are associated with body
processes leading to loss of cartilage [31] or to relevant
changes in the architecture or composition of the bone
[32]. Furthermore, joint healing is strongly dependent
on age, as age is the strongest known risk factor for the
development of OA [33] and depth of injury is also age
associated [34]. Aged cartilage also induces changes in
chondrocyte function and material properties, and
responds differently to cytokines and growth factors
[33].
The location of a particular defect [35] does influence
repair response of the cartilage as well as the mechanical
alignment of the joint [36]. OC lesions are identified most
frequently in the femoral condyles [37], capitellum of the
elbow [38], dome of the talus [30], and the dorsal surface
of the patella [37].Please cite this article in press as: Rodrigues MT, et al. Current strategies for osteochondral regen
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the joint
Homeostasis of articular cartilage depends on mechanical
loads generated during daily activity. Some joint areas are
particularly more affected by weight pressure than others,
which may progress to a more degenerative and diffuse
joint involvement that translates to the patient by causing
pain, swelling, clicking, and instability. Ultimately, inap-
propriate joint loads are associated with focal stress and
result in focal degeneration of cartilage, as that occurs in
OA, and increase the stress on subchondral bone.
Changes in pressure and shear stress induced by joint
movement may induce changes in matrix protein expres-
sion and in the release of nitric oxide associated with joint
pathogenesis [39].
The stress may also vary throughout the cartilage on a
joint surface, because loading is not completely uniform,
leading to gradients in stress and pressure [40]. This
effect is evident in most patients, where the surface of
the joints does not conform perfectly under loading and
may result in an increased risk for OA progression [33].eration: from stem cells to pre-clinical approaches, Curr Opin Biotechnol (2011), doi:10.1016/
www.sciencedirect.com
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Currently available treatments depend upon the size of
the OC defect and the condition of the overlying carti-
lage. Using reparative surgery, cartilage treatments in-
clude arthroscopic debridement, abrasion arthroplasty,
and microfracture. These procedures stimulate the body
to heal the injury, mainly resulting in the formation of
fibrocartilage [41]. Fibrocartilage is a scar tissue present-
ing diminished resilience, reduced stiffness, and poor
wear characteristics when compared to hyaline cartilage.
Thus, fibrocartilage is unlikely to withstand physiological
loading and cannot guarantee to function successfully in
long term. Nevertheless, other options are available with
restorative surgery, namely, autografts recurring to mosai-
coplasty procedures, allografts [42,43] and biologic repla-
cement using cultured autologous chondrocytes [44,45].
The biggest challenge with autografts is to achieve a final
round shape that mimics the surface of the articular joints.
Allograft procedure is similar to autografts [46] andmostly
used after other surgeries have failed. It is not recom-
mended for patients with OA, and the limited supply of
donor tissue is a major problem of this practice.
Autologous chondrocyte transplantation/implantation
[44] has also been described to help restoring the struc-
tural make-up of the articular cartilage. The intermediate
and long-term functional and clinical results are promis-
ing, especially regarding the durability of the repair in
human patients follow-up [45].
More recently [47], tissues from the covering of bone and
cartilage are implanted into the lesion through periosteal
and perichondral grafting to promote the repair and
functionality of cartilage.
Despite the availability of procedures, all current treat-
ment options inflict further tissue destruction before any
therapeutic effect can be achieved.
TE strategies to improve available treatments
Cells to promote healing
Despite current knowledge on OC field, the selection of a
cell source to promote efficient OC regeneration is a major
issue that must to be considered. Ideally, a cell source
should enable insignificant donor morbidity or tissue scar-
city, resurface joints with cartilage, have no limitations in
the amounts available and be easy to maintain/expand in
vitro, be readily available, have no issues of immunogeni-
city or disease transmission risks and be of low cost.
Tissue insufficient supply and morbidity, and host
immune responses and disease transmission risks limit
chondrocyte and osteoblast as ideal cells in OC strategies.
Among adult stem cells, bone marrow mesenchymal stem
cells (BMSCs) [15,16,19,20,22,48–51] and adipose-
derived stem cells (ASCs) [9,12,26,48,50,52] are the most
investigated. Nevertheless, some studies described aPlease cite this article in press as: Rodrigues MT, et al. Current strategies for osteochondral regen
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www.sciencedirect.comhigher chondrogenic [50] and osteogenic [48] potential
of BMSCs when compared to ASCs. The effectiveness of
autologous BMSCs transplantation for the repair of full-
thickness articular cartilage defects was assessed in patel-
lae lesions of two human patients [53]. A similar approach
was also considered to repair full thickness femoral con-
dyle defect in an athlete, who had reattained his previous
activity level and experienced neither pain nor other
complications [27].
Other cell sources, including synovial tissue and perios-
teum-derived stem cells have also showed potential for
osteogenic and chondrogenic differentiation [24,54].
Cells from synovial membrane are harvested with mini-
mal complications at the donor site due to a high self-
regenerative capability [24] of synovial tissue. The peri-
osteum is a specialized fibrous tissue composed of fibro-
blast, osteoblast, and progenitor cells that may also be a
possible cell source for OC TE based on its accessibility,
rapid proliferation and differentiation potential [54].
Furthermore, after skeletal surgery procedures, perios-
teum is often used as a covering layer over tissue to
stimulate local regeneration. Despite the potential, peri-
osteum-derived cells should be more investigated for
cellular therapies [55].
Umbilical cord stem cells (UCSCs) together with amnio-
tic fluid derived stem cells (AFSCs) were also introduced
to cartilage and bone TE [8,23,25] presenting interesting
characteristics, since they are easier to obtain and
represent an almost unlimited stem cell sources. Some
risks were associated with human AFSCs harvesting but,
as pregnant women are older than ever before, amnio-
centesis is likely to become a routine procedure in future
years. More recently, cells from human foetal membranes
and placenta, with similar features to human UCMSCs
and AFSCs, have also been successfully differentiated
into osteogenic and chondrogenic lineages [56]. Although
embryonic stem (ES) cells [57] hoped for a promising
future in regenerative medicine, their use is still ethically
controversial and have major ethical considerations
associated. Notwithstanding that human ES cells express
molecules which could cause immune rejection [57] and
present a high genomic instability [57], ES cell transplan-
tation in a collagen gel has shown to induce the formation
of cartilage tissue [17] under mechanical condition in rats
aiming at OC regeneration.
More recently, iPS technology, where iPS cells are gener-
ated by reprogramming of somatic cells through the
exogenous expression of transcription factors, holds great
promise for regenerative medicine in autologous cell
replacement therapies and in genetic defects by restoring
cellular function [58]. Nevertheless and because of iPS
recent development, cell characterization and in vivo
functionality are to be addressed in bone and cartilage
fields.eration: from stem cells to pre-clinical approaches, Curr Opin Biotechnol (2011), doi:10.1016/
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enable the most successful outcomes in OC regenerative
approaches. Besides intrinsic characteristics of stem cells
from a particular source, other factors should be moni-
tored aiming at a successful strategy; such as final appli-
cation, patient age, defect location and damage size. Cell
culture media to induce chondrogenesis and osteogenesis
of undifferentiated cells or maintain and proliferate
primary chondrocytes and osteoblasts in an ex vivo atmos-
phere are commercially available. However, a common
osteochondrocytic medium to co-culture or simul-
taneously differentiate bone and cartilage cells was not
fully established yet, although some attempts have been
described [8,15,59]. This approach can be advantageous
to simplify cell culturing procedures and, simultaneously,
reduce the time and production costs of an engineered
graft towards a clinical scenario.
Biomaterials: human designs to mimic natural
extracellular material
The implantation of cells in the afflicted area could be a
direct approach in OC strategies, but the request for a
support material to promote regeneration, especially in
large sized defects, is to be critically considered. This idea
is inspired in nature itself as, in the body, the majority of
cells subsist in a 3D world, anchored onto a network of
extracellular matrix (ECM), which scaffolding design
proposes to recreate.
Scaffold characteristics will greatly influence cells and
should mimic the complex and demanding environment
to which cells are exposed to. Besides the tissue structural
support and stimulation, either chemically or mechani-
cally, the optimal scaffold should assist tissue functionality
promoting the easy diffusion of nutrients, growth factors
and cellular waste products [60]. Additionally, the ideal
scaffold should be biocompatible and its biodegradability
adjustable to the time required for tissue regeneration [60].
In the last few years, thousands of scaffolds have been
proposed for reparative strategies made from different
materials and production methodologies, with varying
properties and composition. An OC scaffold should com-
bine the better of the two worlds in a functional and
integrated system. Lots of effort has been undertaken in
order to achieve this goal and the most common approach
is an independent cartilage or bone strategy, likely
because chondrocytes and bone cells present different
function-related characteristics including metabolic and
structural features, yet communicating and interacting, in
a unique culturing system.
Natural based polymers such as agarose [15,61], starch [9],
chitosan [9,13,14,62], silk [14], gellan gum [12], hyaluro-
nic acid [16], collagen [17,63] or blends of these materials
[9,14,18,21], and synthetic materials such as polylactic
acid (PLA) [8], polycaprolactone (PCL) [20] and oligo-Please cite this article in press as: Rodrigues MT, et al. Current strategies for osteochondral regen
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for cartilage applications. Most of these materials are
processed into hydrogel and gel based matrices, which
hold particular relevance for cartilage strategies because
of their high water content, tissue-like elastic properties
and the ability to encapsulate cells [64]. Also, gel struc-
tures partially tolerate shock absorption and deformation
mimicking articular cartilage characteristics.
However, cartilage repair in OC interfaces should be
accompanied by an adequate restoration of the under-
lying subchondral bone, enhancing the in situ integration
of the OC system.
The minerals and the collagen fibres in the matrix are
responsible for bone hardness and resistance. Neverthe-
less, the constant remodelling makes bone very plastic
and capable of internal structural changes according to the
stresses it is subjected to. Thus, bone regeneration
requires scaffolds with high mechanical and osteoconduc-
tive properties, and structurally strong enough to sustain
weight bearing loads and avoid cartilage calcification,
which leads to tissue malfunction and death. Scaffolds
should also be biodegradable to keep up with the natural
bone remodelling process. Despite the brittle behaviour
and low tensile strength, inappropriate for significant
torsion areas such as long bones, hydroxyapatite (HA)
and tricalcium phosphate (TCP) are the most studied
ceramics because of their osteoconductive and high
mechanical properties, and are already used in some
clinical applications [4,6]. Other materials, including silk
[2,7], PCL and PCL blends [1,3,5], and PLA [8], have also
been effectively tested as delivery systems [2] or artificial
ECM [8], mimicking and recreating in some extent the
structural organization of bone [1,3,7].
Some OC approaches successfully evaluated the in vivo
application of scaffolds made of collagen fibrils with HA
nanoparticles without implanted cells [65], which can be
of particular importance if one considers the practical and
commercial standpoint, as theengineeredproduct couldbe
a ready-to-use graft for surgery procedures. Furthermore,
this approach would avoid tissue morbidity and scarcity of
autologous cell sources or even immune reactions from
allogenic sources and problems related to cell culturing
methodologies (e.g. animal origin supplements).
Other strategies focus on the cellular interactions of
implanted cells in the tissue surroundings, considering
the reduced metabolism of cartilage. Chondrocytes in
adult individuals do not divide or establish cell-to-cell
contacts but are responsible to produce cartilage dense
ECM [34], thus maintaining cartilage integrity.
Especially in elder patients, implanted cells could melio-
rate the native ECM properties, and improve the func-
tionality of damaged tissue by stimulating fresh ECMeration: from stem cells to pre-clinical approaches, Curr Opin Biotechnol (2011), doi:10.1016/
www.sciencedirect.com
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Table 1
Overview of the scaffold-cells constructs that have been studied for osteochondral tissue applications in pre-clinical models over the last
few years
Scaffolds Cells Ref.
OPF with gelatin microparticle hydrogel Cell-free/marrow mesenchymal stem cells [49]
PCL/TCP-PCL scaffold Cell-free/marrow mesenchymal stromal cells [20]
Hyaluronic acid gel sponges Autologous mesenchymal stromal cells [16]
Hyaluronate-type I collagen-fibrin scaffold Cell-free/autologous chondrocytes [18]
Hyaluronic acid-atelocollagen/b-TCP bilayered scaffold Cell free/chondrocytes [21]
Collagen/HA gradient scaffold Cell free/autologous chondrocytes [65,66]
Poly(lactide-co-glycolide)/nano-HA scaffold Cell free/marrow mesenchymal stem cells [51]
Polylactic acid (PLA)-coated polyglycolic acid (PGA) scaffold Cell free/autologous marrow mesenchymal stem cells [19]
Collagen/b-TCP bilayered scaffold Cell free [63]production. In bony defects, the integration of cells in the
implant may stimulate bone marrow cells and establish a
metabolic balance favouring the neobone formation.
Furthermore, in critical sized defects, cells are likely to
participate in a molecular communication level bridging
the native tissues to the implant towards a successful OC
regeneration.
Different approaches to design an OC scaffold including
hydrogels [49], combination of two distinct layers
[21,29,62,63] or a gradient scaffold [65], usually an
association of a gel or a foam and a ceramic, have been
developed as alternatives to this problem (Table 1).
These complex scaffolds favour the integration into the
native tissue after implantation and guide the cells, into
the desired phenotype, according to the prearranged
environment created from scaffold physical and chemical
properties.
More recently, emerging approaches include the incorp-
oration of bone and/or cartilage growth factors in scaffolds
[49,63] to stimulate native tissue formation and differen-
tiation in vivo. The inclusion of growth factors can ulti-
mately recruit host cells into the damaged site, initiating a
healing pathway, which could be promising for the treat-
ment of OCDs.
Assisted devices: bioreactor systems
The limited diffusion in static culture environments may
constrain tissue ingrowth in engineered scaffolds. Bio-
reactors are usually designed to control the transport of
nutrients and oxygen to cells in constructs promoting
cellular expansion, and in some cases, enabling mechan-
ical stimulation of cultured cells, thus enhancing cell
differentiation and ECM formation.
The challenge is, once again, finding a compromise con-
sidering the different intrinsic properties of cartilage and
bone tissues. In a bioreactor system, dynamic compression
should be applied for cartilage ECM stimulation while, for
bone, medium perfusion is required to control mass trans-
port and provide shear-stress to stimulate neobone for-Please cite this article in press as: Rodrigues MT, et al. Current strategies for osteochondral regen
j.copbio.2011.04.006
www.sciencedirect.commation. To overcome this issue, studies have focused on
the development of double chamber bioreactors with
physical separation; described to fulfil the needs of tis-
sue-specific mechanical forces for OC stimulation [28,29].
The next step, barely explored, would be the automation
of bioreactors controlled by computer software. The
customization of engineered grafts through the develop-
ment of anatomically moulded surfaces [61] has showed
potential results headed to translational OC interfaces. As
follows bioreactors would be a reliable system of auto-
mation and standardization of cell and scaffold method-
ologies reducing the time and production costs of
functional custom-designed grafts.
In vivo models for osteochondral tissue
engineering
Animal studies still represent an essential tool to under-
stand the biologic behaviour of healing and tissue regen-
eration in vivo, though differences in the anatomy and
metabolism of animal models must be considered in an
experimental setup with human correlations.
Different animal models have been used in OC studies
[16,18–20,21,49,51,63,65]. Rats present distinctive
characteristics, such as athymic nude or transgenic
animals, not easily available in larger animal models. This
model has been used to test the efficacy of a poly(lactide-
co-glycolide)/nano-HA scaffold seeded with undifferen-
tiated mesenchymal stem cells in OC defects [51]. After
12 weeks, defects treated with these constructs showed
smooth and hyaline cartilage with abundant glycosami-
noglycan and collagen type II deposition.
Rabbit also demonstrated to be a successful model for OC
[16,20,21,49], especially in femoral regions with the suc-
cessful application of hyaluronate-atelocollagen/beta-
TCP-hydroxyapatite scaffolds in the patellar grove
[21], which promoted, in some extent, OC regeneration
without the formation of fibrocartilage.
Sheep is also a popular animal model because of their
weight-bearing limbs and with metabolic and bone remo-eration: from stem cells to pre-clinical approaches, Curr Opin Biotechnol (2011), doi:10.1016/
Current Opinion in Biotechnology 2011, 22:1–8
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sequence of events in bone graft incorporation and heal-
ing capacities. An OC interface was evaluated in sheep by
the implantation of a composite scaffold of collagen and
HA with or without autologous chondrocytes into a con-
dyle critical defect [65]. Both conditions showed to
support neobone formation and hyaline-like cartilage
regeneration. With a similar implant, collagen/TCP,
OC regeneration was evaluated in the trochlear groove
of minipigs [63]. Although cells were absent in this
strategy, the in situ incorporation of growth factors in
the construct leads to fibrocartilage formation and partial
reconstruction of the subchondral bone integrity in a
short-term follow-up.
A pilot clinical trial with 13 patients using the collagen/
HA cell free tri-layer scaffold [66] mentioned above
indicated promising results with tissue recovery in some
extent after a six-month follow-up.
Conclusions
The currently available treatments based on ‘damage to
heal approaches’, have a limited success. With an increas-
ing aging population, tissue engineering strategies pro-
vide important cues and hope for the treatment of OC
degeneration. Ultimately, the tissue engineered implant
should be able to stimulate and replace old tissue and
native lethargic cells in order to accomplish both regen-
eration and restoring functions for a successful clinical
achievement.
The challenge stands for the replication of the natural
functional architecture and the translation of promising
strategies towards patient needs. Success lies on the
delicate balance of cartilage and bone characteristics
combined in an engineered graft, and its integration in
vivo. The implant must participate in the regenerative
process, considering the specific properties of each OC
interface, which can only be achieved through the design
of scaffold materials accommodating the specific charac-
teristics of bone and cartilage tissues, and providing stem
cells with the necessary cues to satisfy both tissue cellular
needs. The application of cells in critical defects or elder
patient injuries is likely to be beneficial in stimulating
native cells into the regenerative process. The use of
bioreactors can improve the functionality of such con-
structs, accelerate the production, create custom-made
systems, and reduce time costs for obtaining implants for
OC applications.
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